![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly
Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
January 25, 2021
Eli Lilly’s monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial.
Researchers randomized patients to either receive 4,200 mg of IV-administered bamlanivimab or placebo and saw that after eight weeks of participant follow-up, the 965 participants who tested negative for the virus at baseline saw a 57 percent lower frequency of symptomatic COVID-19 in the drug arm compared to the placebo arm.
For the participants who were nursing home residents, researchers found that there was an 80 percent reduction in the frequency of symptomatic COVID-19 among those who received the monoclonal antibody.
Upcoming Events
-
21Oct